$BRTX
BioRestorative Therapies, Inc. Stock $brtx

$brtx Overview Financials Valuation SEC Filings Company Website

2023 Q4 Form 10-Q Financial Statement

#000149315223040483 Filed on November 13, 2023

Income Statement

Concept	2023 Q4	2023 Q3
Revenue	$19.30K	$30.70K
YoY Change	421.62%	5.86%
Cost Of Revenue
YoY Change
Gross Profit		$30.70K
YoY Change
Gross Profit Margin		100.0%
Selling, General & Admin	$2.559M	$2.260M
YoY Change	-36.21%	-38.07%
% of Gross Profit		7361.56%
Research & Development	$680.6K	$874.8K
YoY Change	1.04%	-11.56%
% of Gross Profit		2849.59%
Depreciation & Amortization	$45.74K	$40.00K
YoY Change	43.84%	28.12%
% of Gross Profit		130.29%
Operating Expenses	$3.240M	$3.135M
YoY Change	-30.85%	-32.41%
Operating Profit		-$3.104M
YoY Change		-32.65%
Interest Expense	$376.2K	$60.00K
YoY Change	223.99%	108.04%
% of Operating Profit
Other Income/Expense, Net	$19.24K	$179.0K
YoY Change	-91.18%	-487.97%
Pretax Income	-$2.825M	-$2.930M
YoY Change	-35.02%	-37.07%
Income Tax
% Of Pretax Income
Net Earnings	-$2.825M	-$2.925M
YoY Change	-35.02%	-37.16%
Net Earnings / Revenue	-14638.45%	-9529.29%
Basic Earnings Per Share		-$0.64
Diluted Earnings Per Share	-$0.60	-$0.64
COMMON SHARES
Basic Shares Outstanding	4.707M shares	4.668M shares
Diluted Shares Outstanding		4.571M shares

Balance Sheet

Concept	2023 Q4	2023 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$11.07M	$12.24M
YoY Change	-24.97%	-25.76%
Cash & Equivalents	$884.4K	$2.437M
Short-Term Investments	$10.18M	$9.800M
Other Short-Term Assets	$305.2K	$330.0K
YoY Change	-15.93%	-7.32%
Inventory
Prepaid Expenses
Receivables	$19.30K	$39.30K
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$11.39M	$12.60M
YoY Change	-24.71%	-25.37%
LONG-TERM ASSETS
Property, Plant & Equipment	$507.5K	$306.3K
YoY Change	94.44%	32.42%
Goodwill
YoY Change
Intangibles	$713.7K	$736.1K
YoY Change	-11.17%	38.81%
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$1.221M	$1.197M
YoY Change	-6.51%	15.96%
TOTAL ASSETS
Total Short-Term Assets	$11.39M	$12.60M
Total Long-Term Assets	$1.221M	$1.197M
Total Assets	$12.61M	$13.80M
YoY Change	-23.26%	-22.99%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$189.4K	$227.4K
YoY Change	10.82%	-51.47%
Accrued Expenses	$874.0K	$549.0K
YoY Change	571.94%	378.82%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$1.063M	$932.6K
YoY Change	141.51%	30.04%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$0.00	$40.00K
YoY Change	-100.0%	-79.87%
Total Long-Term Liabilities	$0.00	$40.00K
YoY Change	-100.0%	-79.87%
TOTAL LIABILITIES
Total Short-Term Liabilities	$1.063M	$932.6K
Total Long-Term Liabilities	$0.00	$40.00K
Total Liabilities	$1.063M	$975.0K
YoY Change	76.46%	6.46%
SHAREHOLDERS EQUITY
Retained Earnings	-$167.1M	-$164.2M
YoY Change	9.44%	10.75%
Common Stock	$471.00	$468.00
YoY Change	27.64%	28.22%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$11.55M	$12.83M
YoY Change
Total Liabilities & Shareholders Equity	$12.61M	$13.80M
YoY Change	-23.26%	-22.99%

Cashflow Statement

Concept	2023 Q4	2023 Q3
OPERATING ACTIVITIES
Net Income	-$2.825M	-$2.925M
YoY Change	-35.02%	-37.16%
Depreciation, Depletion And Amortization	$45.74K	$40.00K
YoY Change	43.84%	28.12%
Cash From Operating Activities	-$1.770M	-$1.180M
YoY Change	12.51%	-18.71%
INVESTING ACTIVITIES
Capital Expenditures	$71.04K	$10.00K
YoY Change	-67.35%	-59.37%
Acquisitions
YoY Change
Other Investing Activities	$173.1K	-$10.00K
YoY Change	-105.57%	-99.9%
Cash From Investing Activities	$102.0K	-$20.00K
YoY Change	-103.07%	-99.8%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	81.34K	1.860M
YoY Change
NET CHANGE
Cash From Operating Activities	-1.770M	-1.180M
Cash From Investing Activities	102.0K	-20.00K
Cash From Financing Activities	81.34K	1.860M
Net Change In Cash	-1.587M	660.0K
YoY Change	-67.59%	-105.81%
FREE CASH FLOW
Cash From Operating Activities	-$1.770M	-$1.180M
Capital Expenditures	$71.04K	$10.00K
Free Cash Flow	-$1.841M	-$1.190M
YoY Change	2.81%	-19.39%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022Q3	BRTX	Gain On Ppp Loan Forgiveness GainOnPppLoanForgiveness		usd
	BRTX	Gain On Ppp Loan Forgiveness GainOnPppLoanForgiveness		usd
	dei	Amendment Flag AmendmentFlag	false
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Entity Central Index Key EntityCentralIndexKey	0001505497
CY2023Q3	BRTX	Gain On Ppp Loan Forgiveness GainOnPppLoanForgiveness		usd
CY2023Q1	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation		usd
CY2023Q2	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation		usd
CY2023Q2	us-gaap	Stock Issued During Period Value Conversion Of Units StockIssuedDuringPeriodValueConversionOfUnits		usd
CY2023Q3	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation		usd
CY2022Q3	BRTX	Stock Issued During Period Value Exchange StockIssuedDuringPeriodValueExchange		usd
CY2022Q3	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation		usd
	BRTX	Gain On Ppp Loan Forgiveness GainOnPppLoanForgiveness		usd
	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities		usd
	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering		usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities		usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod		shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2023-09-30
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-37603
	dei	Entity Registrant Name EntityRegistrantName	BIORESTORATIVE THERAPIES, INC.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	NV
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	30-1341024
	dei	Entity Address Address Line1 EntityAddressAddressLine1	40 Marcus Drive
	dei	Entity Address City Or Town EntityAddressCityOrTown	Melville
	dei	Entity Address State Or Province EntityAddressStateOrProvince	NY
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	11747
	dei	City Area Code CityAreaCode	(631)
	dei	Local Phone Number LocalPhoneNumber	760-8100
	dei	Security12b Title Security12bTitle	Common Stock, $0.0001 par value
	dei	Trading Symbol TradingSymbol	BRTX
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
	dei	Entity Bankruptcy Proceedings Reporting Current EntityBankruptcyProceedingsReportingCurrent	true
CY2023Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	4706917	shares
CY2023Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	2436869	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1676577	usd
CY2023Q3	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	9801837	usd
CY2022Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	13072831	usd
CY2023Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	39300	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	16000	usd
CY2023Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	325931	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	363082	usd
CY2023Q3	us-gaap	Assets Current AssetsCurrent	12603937	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	15128490	usd
CY2023Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	306310	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	261003	usd
CY2023Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	154726	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	241760	usd
CY2023Q3	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	736128	usd
CY2022Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	803438	usd
CY2023Q3	us-gaap	Assets Assets	13801101	usd
CY2022Q4	us-gaap	Assets Assets	16434691	usd
CY2023Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	227355	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	170902	usd
CY2023Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	548954	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	130072	usd
CY2023Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	156310	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	139328	usd
CY2023Q3	us-gaap	Liabilities Current LiabilitiesCurrent	932619	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	440302	usd
CY2023Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	42414	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	162317	usd
CY2023Q3	us-gaap	Liabilities Liabilities	975033	usd
CY2022Q4	us-gaap	Liabilities Liabilities	602619	usd
CY2023Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2023Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	20000000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	20000000	shares
CY2023Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	75000000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	75000000	shares
CY2023Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	4667641	shares
CY2023Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	4667641	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	3677775	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	3677775	shares
CY2023Q3	us-gaap	Common Stock Value CommonStockValue	468	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	369	usd
CY2023Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	177042781	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	168457418	usd
CY2023Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-164231163	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-152640897	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	12826068	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	15832072	usd
CY2023Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	13801101	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	16434691	usd
CY2023Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	30700	usd
CY2022Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	29000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	126500	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	116100	usd
CY2023Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	874824	usd
CY2022Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	989170	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3353960	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2839731	usd
CY2023Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2260319	usd
CY2022Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3649530	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	8772632	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	11568490	usd
CY2023Q3	us-gaap	Operating Expenses OperatingExpenses	3135143	usd
CY2022Q3	us-gaap	Operating Expenses OperatingExpenses	4638700	usd
	us-gaap	Operating Expenses OperatingExpenses	12126592	usd
	us-gaap	Operating Expenses OperatingExpenses	14408221	usd
CY2023Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-3104443	usd
CY2022Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-4609700	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-12000092	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-14292121	usd
CY2023Q3	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	61667	usd
CY2022Q3	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-28841	usd
	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	176070	usd
	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-104465	usd
	BRTX	Gain On Ppp Loan Forgiveness GainOnPppLoanForgiveness	250000	usd
CY2023Q3	BRTX	Grant Income GrantIncome	83333	usd
	BRTX	Grant Income GrantIncome	83333	usd
	BRTX	Grant Income GrantIncome	16654	usd
CY2023Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	33951	usd
CY2022Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-17284	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	150423	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-17284	usd
CY2023Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	178951	usd
CY2022Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-46125	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	409826	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	144905	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-2925492	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-4655825	usd
	us-gaap	Net Income Loss NetIncomeLoss	-11590266	usd
	us-gaap	Net Income Loss NetIncomeLoss	-14147216	usd
CY2023Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.64
CY2023Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.64
CY2022Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.28
CY2022Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.28
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.85
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.85
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-3.93
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-3.93
CY2023Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	4570843	shares
CY2023Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	4570843	shares
CY2022Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	3642215	shares
CY2022Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	3642215	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	4061975	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	4061975	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	3602979	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	3602979	shares
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	15832072	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	1148759	usd
CY2023Q1	us-gaap	Stock Granted During Period Value Sharebased Compensation StockGrantedDuringPeriodValueSharebasedCompensation	2190428	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-5684222	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	13487037	usd
CY2023Q2	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	1164135	usd
CY2023Q2	us-gaap	Stock Granted During Period Value Sharebased Compensation StockGrantedDuringPeriodValueSharebasedCompensation	321534	usd
CY2023Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	411710	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-2980552	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	12403864	usd
CY2023Q3	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	1164135	usd
CY2023Q3	us-gaap	Stock Granted During Period Value Sharebased Compensation StockGrantedDuringPeriodValueSharebasedCompensation	329571	usd
CY2023Q3	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	1853990	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-2925492	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	12826068	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	21596949	usd
CY2022Q1	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	1164135	usd
CY2022Q1	us-gaap	Stock Granted During Period Value Sharebased Compensation StockGrantedDuringPeriodValueSharebasedCompensation	2138949	usd
CY2022Q1	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	72819	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-4816150	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	20156702	usd
CY2022Q2	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	1190350	usd
CY2022Q2	us-gaap	Stock Granted During Period Value Sharebased Compensation StockGrantedDuringPeriodValueSharebasedCompensation	1865297	usd
CY2022Q2	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	48504	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-4675241	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	18585612	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	18585612	usd
CY2022Q3	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	1209231	usd
CY2022Q3	us-gaap	Stock Granted During Period Value Sharebased Compensation StockGrantedDuringPeriodValueSharebasedCompensation	1865297	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-4655825	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	17004315	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	17004315	usd
	us-gaap	Net Income Loss NetIncomeLoss	-11590266	usd
	us-gaap	Net Income Loss NetIncomeLoss	-14147216	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	123022	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	88751	usd
	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	-18598	usd
	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	-19895	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	6318562	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	9554582	usd
	BRTX	Gain On Ppp Loan Forgiveness GainOnPppLoanForgiveness	250000	usd
	BRTX	Noncash Lease Expense NoncashLeaseExpense	87034	usd
	BRTX	Noncash Lease Expense NoncashLeaseExpense	87033	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	23300	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	40000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-37151	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-80135	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	56453	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	417674	usd
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	418882	usd
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-20321	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-102921	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-87945	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-4656785	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-4297412	usd
	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	3690238	usd
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	437842	usd
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	9933562	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	101019	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	222642	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	3151377	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-10156204	usd
	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	411710	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	1853990	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	2265700	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	760292	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-14453616	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	1676577	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	21026727	usd
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	2436869	usd
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	6573111	usd
	us-gaap	Net Income Loss NetIncomeLoss	-11600000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	6300000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-4700000	usd
	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	411710	usd
	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	93551	shares
CY2023Q3	us-gaap	Sale Of Stock Number Of Shares Issued In Transaction SaleOfStockNumberOfSharesIssuedInTransaction	685033	shares
CY2023Q3	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	3.03
CY2023Q3	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	1900000	usd
	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_849_eus-gaap--UseOfEstimates_zPBkiwxWJjac" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86D_zYGbRTRHGtu1">Use of Estimates</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of the unaudited condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, equity-based transactions, revenue and expenses and disclosure of contingent liabilities at the date of the unaudited condensed consolidated financial statements. The Company bases its estimates and assumptions on historical experience, known or expected trends and various other assumptions that it believes to be reasonable. As future events and their effects cannot be determined with precision, actual results could differ from these estimates which may cause the Company’s future results to be affected.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2022Q4	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	175000	usd
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p id="xdx_844_eus-gaap--ConcentrationRiskCreditRisk_zrimLmVrEhFe" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_866_zQGtVUg8LqM8">Concentrations</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial instruments that potentially subject the Company to concentrations of credit risk consist of a cash account in a financial institution. The Company maintains deposits in its cash account in excess of the Federal Deposit Insurance Corporation coverage of $<span id="xdx_908_eus-gaap--CashFDICInsuredAmount_iI_c20230930_zzJHfAlCBZQ8" title="FDIC insured limit">250,000</span>. As of September 30, 2023, the Company has not experienced losses on this account.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The royalties related to the Company’s sublicense comprised all of the Company’s revenue during the three and nine months ended September 30, 2023 and 2022.</span></p>
CY2023Q3	us-gaap	Cash Fdic Insured Amount CashFDICInsuredAmount	250000	usd
CY2023Q3	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	9801837	usd
CY2022Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	13072831	usd
CY2023Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	7753923	shares
CY2022Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	5812428	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	7753923	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	5812428	shares
CY2022Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	803438	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	67310	usd
CY2023Q3	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	736128	usd
CY2023Q3	us-gaap	Employee Related Liabilities Current And Noncurrent EmployeeRelatedLiabilitiesCurrentAndNoncurrent	487500	usd
CY2022Q4	us-gaap	Employee Related Liabilities Current And Noncurrent EmployeeRelatedLiabilitiesCurrentAndNoncurrent	26250	usd
CY2023Q3	BRTX	Accrued General And Administrative Expenses AccruedGeneralAndAdministrativeExpenses	61454	usd
CY2022Q4	BRTX	Accrued General And Administrative Expenses AccruedGeneralAndAdministrativeExpenses	103822	usd
CY2023Q3	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	548954	usd
CY2022Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	130072	usd
CY2023Q3	us-gaap	Sale Of Stock Number Of Shares Issued In Transaction SaleOfStockNumberOfSharesIssuedInTransaction	685033	shares
CY2023Q3	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	3.03
CY2023Q3	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	1900000	usd
CY2023Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	4667641	shares
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	0	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Shares Purchased For Award ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward	629017	shares
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	1745000	shares
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	0	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Shares Purchased For Award ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward	25000	shares
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	122117	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	864639	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	5.08
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	629017	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	2.91
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	26766	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	5.08
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1466890	shares
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	4.17
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	1122671	shares
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	4.69
CY2023Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1493706	usd
CY2022Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	3074528	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	6318553	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	9554570	usd
CY2023Q3	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Share Based Awards Other Than Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions	872304	usd
	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P0Y10M13D
CY2023Q3	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.12	pure
	us-gaap	Operating Lease Cost OperatingLeaseCost	126021	usd
	us-gaap	Operating Lease Cost OperatingLeaseCost	122349	usd
	us-gaap	Lease Cost LeaseCost	126021	usd
	us-gaap	Lease Cost LeaseCost	122349	usd
	us-gaap	Operating Lease Payments OperatingLeasePayments	126021	usd
	us-gaap	Operating Lease Payments OperatingLeasePayments	122349	usd
	BRTX	Operating Lease Liability Reduction OperatingLeaseLiabilityReduction	102921	usd
	BRTX	Operating Lease Liability Reduction OperatingLeaseLiabilityReduction	87945	usd
CY2023Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	154726	usd
CY2022Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	270772	usd
CY2023Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	156310	usd
CY2022Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	134031	usd
CY2023Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	42414	usd
CY2022Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	198724	usd
CY2023Q3	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	42007	usd
CY2023Q3	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	173060	usd
CY2023Q3	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	215067	usd
CY2023Q3	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	16343	usd
CY2023Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	198724	usd

Files In Submission

Name	View Source	Status
brtx-20230930_cal.xml	Edgar Link	unprocessable
0001493152-23-040483-index-headers.html	Edgar Link	pending
0001493152-23-040483-index.html	Edgar Link	pending
0001493152-23-040483.txt	Edgar Link	pending
0001493152-23-040483-xbrl.zip	Edgar Link	pending
brtx-20230930.xsd	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex31-2.htm	Edgar Link	pending
ex32-1.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-q.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
brtx-20230930_lab.xml	Edgar Link	unprocessable
brtx-20230930_pre.xml	Edgar Link	unprocessable
brtx-20230930_def.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
form10-q_htm.xml	Edgar Link	completed
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$BRTX
BioRestorative Therapies, Inc. Stock $brtx

2023 Q4 Form 10-Q Financial Statement

#000149315223040483 Filed on November 13, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$BRTX BioRestorative Therapies, Inc. Stock $brtx

2023 Q4 Form 10-Q Financial Statement

#000149315223040483 Filed on November 13, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$BRTX
BioRestorative Therapies, Inc. Stock $brtx